Management of Patients with Renal Failure Undergoing Dialysis During 131I Therapy for Thyroid Cancer

Conclusion: In hemodialysis patients with thyroid cancer, an 131I activity approximately 30% lower than the nominal dose appears to strike an appropriate balance between absence of BM toxicity and therapeutic efficacy. To avoid overirradiation, we recommend pretherapeutic dosimetry studies for metastatic patients to calculate the amount of activity to be administered. We also recommend dosimetry monitoring during the hemodialysis sessions performed after therapeutic dose administration and under the same conditions.

Source: Journal of Nuclear Medicine - August 2, 2020 Category: Nuclear Medicine Authors: Vermandel, M., Debruyne, P., Beron, A., Devos, L., Talbot, A., Legrand, J.-F., Provot, F., Lion, G. Tags: Clinical Source Type: research